The Panic Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Panic Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Panic Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Panic Disorders and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Panic Disorders by nine companies/universities/institutes. The top development phase for Panic Disorders is phase ii with four drugs in that stage. The Panic Disorders pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Panic Disorders pipeline products market are: Johnson & Johnson, New York University and Bionomics.
The key targets in the Panic Disorders pipeline products market include Cannabinoid Receptor 1, Cannabinoid Receptor 2, and 5-Hydroxytryptamine Receptor 1A.
The key mechanisms of action in the Panic Disorders pipeline product include 5-Hydroxytryptamine Receptor 1A Agonist with two drugs in Preclinical. The Panic Disorders pipeline products include two routes of administration with the top ROA being Oral and one key molecule types in the Panic Disorders pipeline products market including Small Molecule.
Panic Disorders overview
Panic disorder is an anxiety disorder characterized by regular, sudden attacks of fear. Patients with this disorder have feelings of anxiety, stress, and panic regularly and at any time, often for no apparent reason. Symptoms may include a racing heartbeat, feeling faint, sweating, nausea, and chest pain.
For a complete picture of Panic Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
